Evidence map›Paper›PMID 34185704›Full record

ArticleJCI insight2021

IL-13 is a driver of COVID-19 severity.

Alexandra N Donlan, Tara E Sutherland, Chelsea Marie, Saskia Preissner, Benjamin T Bradley, Rebecca M Carpenter, Jeffrey M Sturek, Jennie Z Ma, G Brett Moreau, Jeffrey R Donowitz and 17 more

Open access · goldAbstract read
In one paragraph

Article in JCI insight, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 117 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
117citing papers in PubMed, 1 pooled it
9.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

117 citing papers in PubMed, 1 synthesis or guideline pooled it, 157 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Oral hymecromone decreases hyaluronan in human study participants.The Journal of clinical investigation · 2022
    Trial
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Hyaluronan Ameliorates Viral Pneumonia in Mice and Humans by Inhibiting Transcription Factor E2F1.American journal of respiratory cell and molecular biology · 2026
    Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

57 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

27 authors at 8 institutions in 4 countries.

Alexandra N DonlanDivision of Infectious Diseases and International Health, Department of Medicine and.
Tara E SutherlandLydia Becker Institute of Immunology and Inflammation, School of Biological Sciences, University of Manchester, Manchester Academic Health Sciences Centre, Manchester, United Kingdom.
Chelsea MarieDivision of Infectious Diseases and International Health, Department of Medicine and.
Saskia PreissnerDepartment Oral and Maxillofacial Surgery, Charité - Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Benjamin T BradleyDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.
Rebecca M CarpenterDivision of Infectious Diseases and International Health, Department of Medicine and.
Jeffrey M SturekDivision of Pulmonary and Critical Care Medicine, Department of Medicine and.
Jennie Z MaDepartment of Public Health Sciences, University of Virginia School of Medicine, Charlottesville, Virginia, USA.
G Brett MoreauDivision of Infectious Diseases and International Health, Department of Medicine and.
Jeffrey R DonowitzDivision of Infectious Diseases and International Health, Department of Medicine and.
Gregory A BuckDepartment of Microbiology and Immunology, School of Medicine, Virginia Commonwealth University, Richmond, Virginia, USA.
Myrna G SerranoDepartment of Microbiology and Immunology, School of Medicine, Virginia Commonwealth University, Richmond, Virginia, USA.
Stacey L BurgessDivision of Infectious Diseases and International Health, Department of Medicine and.
Mayuresh M AbhyankarDivision of Infectious Diseases and International Health, Department of Medicine and.
Cameron MuraSchool of Data Science and Department of Biomedical Engineering University of Virginia, Charlottesville, Virginia, USA.
Philip E BourneSchool of Data Science and Department of Biomedical Engineering University of Virginia, Charlottesville, Virginia, USA.
Robert PreissnerScience-IT and Institute of Physiology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Mary K YoungDivision of Infectious Diseases and International Health, Department of Medicine and.
Genevieve R LyonsDepartment of Public Health Sciences, University of Virginia School of Medicine, Charlottesville, Virginia, USA.
Johanna J LoombaIntegrated Translational Health Research Institute (iTHRIV) and.
Sarah J RatcliffeDepartment of Public Health Sciences, University of Virginia School of Medicine, Charlottesville, Virginia, USA.
Melinda D PoulterDepartment of Pathology, University of Virginia School of Medicine, Charlottesville, Virginia, USA.
Amy J MathersDivision of Infectious Diseases and International Health, Department of Medicine and.
Anthony J DayLydia Becker Institute of Immunology and Inflammation, School of Biological Sciences, University of Manchester, Manchester Academic Health Sciences Centre, Manchester, United Kingdom.
Barbara J MannDivision of Infectious Diseases and International Health, Department of Medicine and.
Judith E AllenLydia Becker Institute of Immunology and Inflammation, School of Biological Sciences, University of Manchester, Manchester Academic Health Sciences Centre, Manchester, United Kingdom.
William A PetriDivision of Infectious Diseases and International Health, Department of Medicine and.
Office of Infectious Diseases · USUniversity of Virginia · USManchester Academic Health Science Centre · GBHumboldt-Universität zu Berlin · DEVirginia Commonwealth University · USPulmonary and Critical Care Associates · USTranslational Research Institute · AUUniversity of Washington · US

Funding

CD2H - The National COVID Cohort Collaborative (N3C) IDeA CTR CollaborationU24TR002306 · NCATS · UNIVERSITY OF COLORADO DENVER · PI CHUTE, CHRISTOPHER G, EICHMANN, DAVID A. · 2017 to 2021
$28.9M
The integrated Translational Health Research Institute of Virginia (iTHRIV): Using Data to Improve HealthUL1TR003015 · NCATS · UNIVERSITY OF VIRGINIA · PI BROWN, DONALD E, JOHNSTON, KAREN C. · 2019 to 2023
$20.3M
Role of Type 2 Immunity in Innate Protection from C. difficileR01AI124214 · NIAID · UNIVERSITY OF VIRGINIA · PI William A Petri · 2016 to 2026
$5.4M
Institutional Career Development CoreKL2TR003016 · NCATS · UNIVERSITY OF VIRGINIA · PI PAPIN, JASON, WORRALL, BRADFORD B · 2019 to 2023
$3.9M
Role of Host Protein Kinase C in CryptosporidiosisR01AI148518 · NIAID · UNIVERSITY OF VIRGINIA · PI MARIE, CHELSEA S. · 2020 to 2024
$3.3M
Gut microbiome communication with the bone marrow regulates intestinal inflammation.R01AI146257 · NIAID · UNIVERSITY OF VIRGINIA · PI BURGESS, STACEY L · 2020 to 2025
$2.0M
Interdisciplinary Training in Systems & Biomolecular Data ScienceT32GM145443 · NIGMS · UNIVERSITY OF VIRGINIA · PI Kevin A Janes, Jason Papin · 2022 to 2026
$1.5M
Medical Research Council MR/K01207X/2NCATS NIH HHS KL2 TR003016NCATS NIH HHS U24 TR002306NCATS NIH HHS UL1 TR003015NIAID NIH HHS R01 AI124214NIAID NIH HHS R01 AI146257NIAID NIH HHS R01 AI148518NIGMS NIH HHS T32 GM145443Wellcome Trust
6 · The paper itself

Abstract

Immune dysregulation is characteristic of the more severe stages of SARS-CoV-2 infection. Understanding the mechanisms by which the immune system contributes to COVID-19 severity may open new avenues to treatment. Here, we report that elevated IL-13 was associated with the need for mechanical ventilation in 2 independent patient cohorts. In addition, patients who acquired COVID-19 while prescribed Dupilumab, a mAb that blocks IL-13 and IL-4 signaling, had less severe disease. In SARS-CoV-2-infected mice, IL-13 neutralization reduced death and disease severity without affecting viral load, demonstrating an immunopathogenic role for this cytokine. Following anti-IL-13 treatment in infected mice, hyaluronan synthase 1 (Has1) was the most downregulated gene, and accumulation of the hyaluronan (HA) polysaccharide was decreased in the lung. In patients with COVID-19, HA was increased in the lungs and plasma. Blockade of the HA receptor, CD44, reduced mortality in infected mice, supporting the importance of HA as a pathogenic mediator. Finally, HA was directly induced in the lungs of mice by administration of IL-13, indicating a new role for IL-13 in lung disease. Understanding the role of IL-13 and HA has important implications for therapy of COVID-19 and, potentially, other pulmonary diseases. IL-13 levels were elevated in patients with severe COVID-19. In a mouse model of the disease, IL-13 neutralization reduced the disease and decreased lung HA deposition. Administration of IL-13-induced HA in the lung. Blockade of the HA receptor CD44 prevented mortality, highlighting a potentially novel mechanism for IL-13-mediated HA synthesis in pulmonary pathology.

Indexed as

AnimalsCOVID-19Disease Models, AnimalDisease ProgressionFemaleHumansInterleukin-13LungMaleMiceMice, Inbred C57BLSARS-CoV-2Severity of Illness IndexInterleukin-13COVID-19CytokinesImmunologyInnate immunityTh2 response

Identifiers

PMID34185704
PMCPMC8410056
OpenAlexW3173905692

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.